Sign In
Buy RCKT
$3.11
-0.100 (-3.12%)
At Close: Jul 31, 2026
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Friday, 10'th Oct 2025
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder
07:11am, Friday, 03'rd Oct 2025
Rocket Pharmaceuticals said on Friday that it has withdrawn its application for U.S approval of its experimental gene therapy for a rare inherited blood disorder.
Kuehn Law Encourages Investors of Rocket Pharmaceuticals, Inc. to Contact Law Firm
01:30pm, Friday, 19'th Sep 2025
NEW YORK , Sept. 19, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) bre
Rocket Pharmaceuticals, Inc. (RCKT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
12:36pm, Tuesday, 09'th Sep 2025
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 9:15 AM EDT Company Participants Gaurav Shah - CEO & Director Conference Call Part
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
07:00am, Thursday, 28'th Aug 2025
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study
12:15pm, Thursday, 21'st Aug 2025
Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.
Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.
11:02am, Wednesday, 20'th Aug 2025
The past year has been a disappointing one for gene therapies.
FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy
09:31am, Wednesday, 20'th Aug 2025
Rocket Pharmaceuticals Inc. RCKT stock is trading higher on Wednesday after the U.S. Food and Drug Administration (FDA) lifted the clinical hold on its pivotal Phase 2 trial of RP-A501 for Danon dise
US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial
07:09am, Wednesday, 20'th Aug 2025
Rocket Pharmaceuticals said on Wednesday that the U.S. Food and Drug Administration has lifted the clinical hold on its gene therapy mid-stage trial.
Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease
07:00am, Wednesday, 20'th Aug 2025
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.
BENSALEM, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
11:59am, Monday, 11'th Aug 2025
NEW YORK--(BUSINESS WIRE)---- $RCKT #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rocket Pharmaceuticals, Inc. (“Rocket” or
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT). Such inve
